• For this trial, we are looking for participants of European ancestry. This information focuses on participants of European descent.
• In this study we will investigate how safe the new compound is and how well it is tolerated when it is used by healthy participants of different ancestries.
• The study compound is a new compound that may potentially be used for the treatment of a kidney disease called autosomal dominant polycystic kidney disease (ADPKD). This kidney disease is a hereditary condition in which cysts gradually develop in the kidneys. A cyst is a fluid-filled sac (a kind of sac). These cysts often lead to kidney enlargement and high blood pressure. Eventually, so many cysts can grow that they crowd out normal kidney tissue. The kidneys then stop functioning properly. ADPKD is one of the most common hereditary kidney diseases, usually presenting symptoms in adults. The new compound is developed to block signals in the body that make the cysts in the kidney grow. This can cause the kidneys to grow more slowly and function longer. However, this does not cure the disease.
• You will be given the study compound once as four injections of 1.5 mL under the skin of the abdomen.

The compound has been tested in healthy individuals and patients with ADPKD.

• You are a healthy male or female.
• You and your 2 parents and 4 grandparents were born in Europe.
• You are at least 25 and at most 55 years old.
• Your weight is at least 50 kg (males) and 45 kg (females) and your Body Mass Index (BMI) is at least 18.0 and at most 28.0 kg/m². 
• Both non-smokers and smokers or occasional smokers are allowed to participate in this clinical trial. During your stay in our research facility, you are not allowed to smoke.

• As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:
  • You have passed menopause (no periods for at least 12 months);
  • You have been sterilized.
• The are no contraceptive requirements for males.

Note:

• You cannot participate in the trial if you have participated in another clinical trial in the 30 days prior to the first administration of the compound in this clinical trial (counting from the last compound administration). This may be longer for certain trials. Please contact us for more information.
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.

The trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 9 days (8 nights), followed by 6 short visits. The follow-up will take place during the final short visit.

Note: You must be available for all dates to be able to participate in this clinical trial.